542
Views
4
CrossRef citations to date
0
Altmetric
Brief Report

Intravenous esketamine leads to an increase in impulsive and suicidal behaviour in a patient with recurrent major depression and borderline personality disorder

, , , , &
Pages 715-718 | Received 28 Sep 2021, Accepted 16 Jan 2022, Published online: 08 Mar 2022

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Maria Gałuszko-Węgielnik, Katarzyna Jakuszkowiak-Wojten, Alina Wilkowska & Wiesław Jerzy Cubała. (2023) Short term ketamine treatment in patient with bipolar disorder with comorbidity with borderline personality disorder: Focus on impulsivity. The World Journal of Biological Psychiatry 24:9, pages 849-853.
Read now
Bartłomiej Pochwat, Anna Julia Krupa, Marcin Siwek & Bernadeta Szewczyk. (2022) New investigational agents for the treatment of major depressive disorder. Expert Opinion on Investigational Drugs 31:10, pages 1053-1066.
Read now

Articles from other publishers (2)

. (2023) Multiple drugs. Reactions Weekly 1938:1, pages 978-978.
Crossref
Neethu K Nandan, Puneet K Soni, Ajay Parsaik & Aqeel Hashmi. (2022) “Esketamine” in Borderline Personality Disorder: A Look Beyond Suicidality. Cureus.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.